Elucid

Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care

Elucid provides phone, email, and form contacts for information about Plaque-IQ and product demos.

Plaque-IQ is FDA-cleared CTA software that quantifies coronary and carotid plaque morphology using non-invasive CT scans.

Elucid announces an oversubscribed $55 million Series D financing with participation from IAG Capital Partners, Elevage Medical Technologies, and an unnamed publicly traded medtech strategic investor. The company says it will use the proceeds to support commercial expansion of its coronary CT plaque analysis and its pending BioIntegrated FFR-CT submission.

Sep 2026 · ElucidNews article

Elucid enrolls the first patient in AI-PREDICT, an international study designed to define cardiovascular risk at the individual coronary-lesion level. The study uses the company's CT-based plaque characterization as its measurement method.

Jul 2026 · ElucidNews article

Elucid's Plaque-IQ software is named Best New Cardiology Technology Solution in the 2026 MedTech Breakthrough Awards. The program recognizes the product in its cardiology technology category for histology-validated plaque characterization from coronary CT angiography.

May 2026 · ElucidNews article

Elucid makes its lesion inspection tool commercially available within Plaque-IQ. The feature lets clinicians examine individual coronary lesions within an existing plaque analysis.

Apr 2026 · ElucidNews article